High-throughput screening based identification of small molecule antagonists of integrin CD11b/CD18 ligand binding

Biochemical and Biophysical Research Communications

Volumn 394, Issue 1, 2010, Pages 194-199

  Faridi, Mohd Hafeez ^a   Maiguel, Dony ^a   Brown, Brock T ^b   Suyama, Eigo ^b   Barth, Constantinos J ^a   Hedrick, Michael ^b   Vasile, Stefan ^b   Sergienko, Eduard ^b   Schürer, Stephan ^c   Gupta, Vineet ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Adhesion assay; CD11b CD18; HTS assay; Inhibitor; Integrin; Screening

Indexed keywords

CD11B ANTIGEN; CD18 ANTIGEN; FIBRINOGEN; INTEGRIN; MEVINOLIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 44A; MONOCLONAL ANTIBODY IB4; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ADHESION; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD18; HIGH-THROUGHPUT SCREENING ASSAYS; LIGANDS; MICE; MICE, INBRED STRAINS; NEUTROPHILS; SMALL MOLECULE LIBRARIES;

EID: 77949874762     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.02.151     Document Type: Article

References (35)

1. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110 (2002) 673-687
2. Arnaout M.A. Leukocyte adhesion molecules deficiency: its structural basis, pathophysiology and implications for modulating the inflammatory response. Immunol. Rev. 114 (1990) 145-180
3. Horwitz A.F. Integrins and health. Sci. Am. 276 (1997) 68-75
4. McDowall A., Inwald D., Leitinger B., Jones A., Liesner R., Klein N., and Hogg N. A novel form of integrin dysfunction involving beta1, beta2, and beta3 integrins. J. Clin. Invest. 111 (2003) 51-60
5. Hogg N., and Leitinger B. Shape and shift changes related to the function of leukocyte integrins LFA-1 and Mac-1. J. Leukoc. Biol. 69 (2001) 893-898
6. Plow E.F., Haas T.A., Zhang L., Loftus J., and Smith J.W. Ligand binding to integrins. J. Biol. Chem. 275 (2000) 21785-21788
7. Soriano S.G., Coxon A., Wang Y.F., Frosch M.P., Lipton S.A., Hickey P.R., and Mayadas T.N. Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. Stroke 30 (1999) 134-139
8. Simon D.I., Dhen Z., Seifert P., Edelman E.R., Ballantyne C.M., and Rogers C. Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. J. Clin. Invest. 105 (2000) 293-300
9. Tang T., Rosenkranz A., Assmann K.J., Goodman M.J., Gutierrez-Ramos J.C., Carroll M.C., Cotran R.S., and Mayadas T.N. A role for Mac-1 (CDIIb/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcgamma receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis. J. Exp. Med. 186 (1997) 1853-1863
10. Yonekawa K., and Harlan J.M. Targeting leukocyte integrins in human diseases. J. Leukoc. Biol. 77 (2005) 129-140
11. Jaeschke H., Farhood A., Bautista A.P., Spolarics Z., Spitzer J.J., and Smith C.W. Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. Hepatology 17 (1993) 915-923
12. Rogers C., Edelman E.R., and Simon D.I. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc. Natl. Acad. Sci. USA 95 (1998) 10134-10139
13. Dove A. CD18 trials disappoint again. Nat. Biotechnol. 18 (2000) 817-818
14. Ramamoorthy C., Sasaki S.S., Su D.L., Sharar S.R., Harlan J.M., and Winn R.K. CD18 adhesion blockade decreases bacterial clearance and neutrophil recruitment after intrapulmonary E. coli, but not after S. aureus. J. Leukoc. Biol. 61 (1997) 167-172
15. Krams M., Lees K.R., Hacke W., Grieve A.P., Orgogozo J.M., and Ford G.A. Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 34 (2003) 2543-2548
16. Zerria K., Jerbi E., Hammami S., Maaroufi A., Boubaker S., Xiong J.P., Arnaout M.A., and Fathallah D.M. Recombinant integrin CD11b A-domain blocks polymorphonuclear cells recruitment and protects against skeletal muscle inflammatory injury in the rat. Immunology 119 (2006) 431-440
17. Feng Y., Chung D., Garrard L., McEnroe G., Lim D., Scardina J., McFadden K., Guzzetta A., Lam A., Abraham J., Liu D., and Endemann G. Peptides derived from the complementarity-determining regions of anti-Mac-1 antibodies block intercellular adhesion molecule-1 interaction with Mac-1. J. Biol. Chem. 273 (1998) 5625-5630
18. Xiong J.P., Li R., Essafi M., Stehle T., and Arnaout M.A. An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain. J. Biol. Chem. 275 (2000) 38762-38767
19. Huth J.R., Olejniczak E.T., Mendoza R., Liang H., Harris E.A., Lupher Jr. M.L., Wilson A.E., Fesik S.W., and Staunton D.E. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. Proc. Natl. Acad. Sci. USA 97 (2000) 5231-5236
20. Kallen J., Welzenbach K., Ramage P., Geyl D., Kriwacki R., Legge G., Cottens S., Weitz-Schmidt G., and Hommel U. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol. 292 (1999) 1-9
21. Shimaoka M., and Springer T.A. Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Discov. 2 (2003) 703-716
22. Bansal V.S., Vaidya S., Somers E.P., Kanuga M., Shevell D., Weikel R., and Detmers P.A. Small molecule antagonists of complement receptor type 3 block adhesion and adhesion-dependent oxidative burst in human polymorphonuclear leukocytes. J. Pharmacol. Exp. Ther. 304 (2003) 1016-1024
23. Park J.Y., Arnaout M.A., and Gupta V. A simple, no-wash cell adhesion-based high-throughput assay for the discovery of small-molecule regulators of the integrin CD11b/CD18. J. Biomol. Screen. 12 (2007) 406-417
24. Zhang J.H., Chung T.D., and Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-73
25. Pipeline Pilot 7.5, Accelrys, San Diego, 2009.
26. Leadscope Enterprise, Leadscope Inc., Columbus, 2007.
27. Chen L.Y., Shieh J.J., Lin B., Pan C.J., Gao J.L., Murphy P.M., Roe T.F., Moses S., Ward J.M., Lee E.J., Westphal H., Mansfield B.C., and Chou J.Y. Impaired glucose homeostasis, neutrophil trafficking and function in mice lacking the glucose-6-phosphate transporter. Hum. Mol. Genet. 12 (2003) 2547-2558
28. Bergmeier W., Goerge T., Wang H.W., Crittenden J.R., Baldwin A.C., Cifuni S.M., Housman D.E., Graybiel A.M., and Wagner D.D. Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J. Clin. Invest. 117 (2007) 1699-1707
29. Ortlepp S., Stephens P.E., Hogg N., Figdor C.G., and Robinson M.K. Antibodies that activate beta 2 integrins can generate different ligand binding states. Eur. J. Immunol. 25 (1995) 637-643
30. Beals C.R., Edwards A.C., Gottschalk R.J., Kuijpers T.W., and Staunton D.E. CD18 activation epitopes induced by leukocyte activation. J. Immunol. 167 (2001) 6113-6122
31. Masumoto A., and Hemler M.E. Mutation of putative divalent cation sites in the alpha 4 subunit of the integrin VLA-4: distinct effects on adhesion to CS1/fibronectin, VCAM-1, and invasin. J. Cell Biol. 123 (1993) 245-253
32. Wright S.D., Rao P.E., Van Voorhis W.C., Craigmyle L.S., Iida K., Talle M.A., Westberg E.F., Goldstein G., and Silverstein S.C. Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies. Proc. Natl. Acad. Sci. USA 80 (1983) 5699-5703
33. V. Gupta, HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay. Pubchem Assay ID 1497, 2009.
34. Guha R., and Schurer S.C. Utilizing high throughput screening data for predictive toxicology models: protocols and application to MLSCN assays. J. Comput. Aided Mol. Des. 22 (2008) 367-384
35. Blower Jr. P.E., Cross K.P., Fligner M.A., Myatt G.J., Verducci J.S., and Yang C. Systematic analysis of large screening sets in drug discovery. Curr. Drug Discov. Technol. 1 (2004) 37-47